J. Helterbrand

发表

Universal cokriging under intrinsic coregionalization

N. Cressie, J. Helterbrand, 1994 .

A statistical approach to identifying closed object boundaries in images

N. Cressie, J. Helterbrand, J. Davidson, 1994, Advances in Applied Probability.

Object Identification Using Markov Random Field Segmentation Models at Multiple Resolutions of a Rectangular Lattice

N. Cressie, J. Helterbrand, 1997 .

Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.

J. Helterbrand, H. Burger, J. Denne, 2011, European journal of cancer.

Pharmacokinetic‐pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis

J. Helterbrand, J. Dhainaut, M. Seger, 2002, Clinical pharmacology and therapeutics.

Low levels of protein C are associated with poor outcome in severe sepsis.

J. Helterbrand, G. Bernard, T. Wright, 2001, Chest.

RECOMBINANT HUMAN ACTIVATED PROTEIN C (rhAPC) PRODUCES A TREND TOWARD IMPROVEMENT IN MORBIDITY AND 28 DAY SURVIVAL IN PATIENTS WITH SEVERE SEPSIS

J. Helterbrand, G. Bernard, C. Fisher, 1999 .

C-spine rule for radiography in trauma patients

J. Helterbrand, J. Vincent, P. Ferdinande, 2002 .

Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei.

J. Helterbrand, C. Fisher, A. Simpson, 2006, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000)

Gary Garber, Jay Steingrub, Pierre-François Laterre, 2001 .

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

J. Helterbrand, G. Bernard, J. Vincent, 2003, Critical care medicine.

Efficacy and safety of recombinant human activated protein C for severe sepsis

J. Helterbrand, J. Barkun, G. Bernard, 2003 .

Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications

José A Fernández, J. Helterbrand, J. Griffin, 2000, Critical care medicine.

Cox Regression Methods for Two‐Stage Randomization Designs

Yuliya Lokhnygina, J. Helterbrand, Y. Lokhnygina, 2007, Biometrics.

Spatial dependence models and image analysis

Jeffrey Donald Helterbrand, J. Helterbrand, 1993 .

Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.

D J Sargent, J. Helterbrand, D. Sargent, 2011, European journal of cancer.

Two‐stage randomization designs in drug development

J. Helterbrand, M. Wolbers, 2008, Statistics in medicine.

Early goal-directed therapy in the treatment of severe sepsis and septic shock

J. Helterbrand, P. Singer, T. Evans, 2002 .

Design and methods of the Raloxifene Use for The Heart (RUTH) study.

J. Helterbrand, E. Barrett-Connor, L. Mosca, 2001, The American journal of cardiology.

Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei.

J. Helterbrand, S. Opal, W. Chaowagul, 2006 .